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Abstract: When it comes to cell proliferation, this is a process strictly controlled by extracellular signals, such as nutrients, growth 
factors, temperature, and more. Together, these establish the cell cycle control mechanism, which is the core of cell proliferation. 
Throughout the current review, a collection of the most pertinent background sources was built, in order to investigate the 
cytoprotective effect of cooling in opposition to toxicity brought on by chemotherapy, and subsequently another experimental approach 
was developed to comprehend the impacts of cooling on cell cycle arrest in cell culture. As a result, it is considered that this could show 
an approach for reaching selective toxicity of chemotherapeutic agents for cells, which in turn can provide a deeper comprehension of 
the molecular and cellular processes occurring within. With detailed information collected regarding the way that cell cycle events are 
controlled, it is considered that innovative ways of using this to protect for chemotherapy-induced alopecia will be established. 
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1. Introduction 
 
The cell cycle is the fundamental means by which every 
living entity divides and multiplies. The cell cycle is divided 
into four main phases: G1 phase (Gap phase 1) where the 
nucleus has the two complementary strands of DNA; S-phase 
(synthesis) during which DNA replication takes place, and 
G2 phase (Gap phase 2) preceding mitosis (M phase). Some 
cells are either not in an active cycle (post-mitotic) or have 
become quiescent and entered a resting phase known as G0; 
during this time when the cell receives a mitotic signal it can 
re-enter the G1 phase [1]. In order to preserve the stability of 
the genome in response to cellular damage, there are 
monitoring mechanisms (checkpoints) that will arrest the 
cycle at either G1/S or G2/M. In turn, this is able to offer 
extra opportunities for the cells to activate the repair 
processes, in order to extract damage prior to DNA 
replication. Also, if damage is excessive and/or repair cannot 
occur, cell death by apoptosis can be stimulated [2, 3]. Cell 
division is a complex, finely tuned mechanism. In each cell 
cycle phase, the cell monitors both its own growth as well as 
the external conditions. If these are unfavorable then growth 
arrest or cell cycle arrest is initiated [4]. 
 
One critical period for cell cycle progression exists, which is 
the G1/S phase boundary [5, 6]. This period is called the 
restriction point (R point) in the mammalian cell cycle [7]. It 
is a point in the G1 phase at which the cell committed to 
the cell cycle and after which extracellular proliferation 
stimulants are no longer required [1]. Once it progresses 
through the point of R point, the cell cycle progress to enter S 
phase and the cells initiate DNA synthesis promptly, then on 
to G2 phase, and the M phase continuously [8, 9]. If the 
decision is made that the environment is bad, the cell cannot 
go through the start, so it will stay in the G1 phase as it is not 
proceeding to the S phase, or remain in the stationary phase 
G0 phase and enter a dormant state [10]. The environment of 
the cell placement decides whether there are signals to go 
forward, e.g. differentiation, aging, apoptosis, meiosis, but 
the main aim of those states'  point of branching to those 
states is also present at this point in the G1 period it is 
considered [11]. 
 
The restriction point may be deregulated in cancer cells, at 
which point the withdrawal of growth factors no longer 
induces reversion to a quiescent state and the abnormal 
cancer cells continue to proliferate ignoring the signal of 
mitotic arrest coming from surrounding cells [12]. 
 
Moreover, the distribution of cells at different stages of the 
cycle determines cell growth rates and usually S phase 
percentage reflects the quantity of multiplying cells. Cancers 
tend to have a higher percentage of S phase cells than that of 
normal tissues. Furthermore, more aggressive cancer types 
have a higher proportion of cells in the S phase compared to 
less aggressive tumours [12-14]. 
 
2. Effects of Chemotherapeutic Agents on the 
Cell Cycle 
 
Since many chemotherapy drugs are only effective on 
actively dividing cells and not those that are in a quiescent or 
dormant stage (and out of cycle), cell cycle analysis is 
important in helping to understand their mechanism of action. 
Chemotherapeutic drugs primarily target DNA synthesis and 
the proteins critical for normal mitosis by targeting specific 
stages of the cell cycle, as explained below and summarised 
in Figure 1 [15]. When chemotherapy drugs induce DNA 
damage, either the cell cycle can be arrested temporarily to 
allow for DNA repair [16] or the cells could be eliminated by 
apoptosis [17]. This is a decision-making process, where the 
tumour suppressor p53 plays a vital role. 
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Many chemotherapeutic drugs interfere with cellular 
metabolism and trigger apoptosis [18, 19]. It is seen that 
there are varying levels of stress with different impacts on 
cells. Mild stress can trigger repair mechanisms, which can 
aid in cell survival. Low or moderate stress (damage) 
activates apoptosis, while extremely high stress overwhelms 
apoptosis and leads to necrosis. An unregulated catastrophic 
mode of cell death occurs when the cell is intensely damaged 
or stressed. Chemotherapeutic drug treatment can induce 
apoptosis, indicating that cells initiate a controlled suicide in 
which the cell passes through different phases and eventually 
fragmentation (DNA) in cells is observed, thus apoptosis is a 
means that can allow an organism to eliminate damaged cells 
in an orderly fashion [19]. 
 
Chemotherapeutic drugs can be classified as cell cycle 
specific and non-specific drugs. Certain chemotherapeutic 
agents are meant to impact dividing cells throughout one or 
more phases of the cell cycle, through  bringing on  arrest 
either in G1/S or G2/M phases; for example docetaxel acts 
on cells in G2 and M phases by exhibiting high affinity to β-
tubulin and targeting centrosome organization [20]. By 
contrast, docetaxel has minimal effects on cells in G1 phase 
and as a result there is an accumulation of the cells in G2/M 
phase [20]. Doxorubicin induces G2/M arrest in cell cycle 
progression [21]. Other drugs, such as cyclophosphamide, 
may affect dividing cells in all phases of the cycle, and as 
such are non-cell cycle specific [21]. 
 
 
Figure 1: Chemotherapy drugs and their point of action in 
the cell cycle 
 
This diagram shows a schematic depiction of the cell cycle 
and its different stages. This displays the point of action 
throughout the cell cycle for numerous chemotherapy drugs 
widely employed in clinical settings. Importantly, even 
though all drugs are shown as being connected with certain 
cell cycles stages, usually a phase-overlap exists since certain 
chemotherapy agents can be aimed at two or greater phases, 
including overlapping phases, of the cell cycle. On the other 
hand, others can act on cells regardless of the phase, and are 
cell cycle independent.  G0 means that the cell is out of 
cycle, known as quiescence. G1 is where the cell is about to 
divide and releases a number of proteins necessary for DNA 
replication. S is where DNA double-stranded breaks are 
brought on by topoisomerase enzymes, and DNA replication 
occurs. G2 involves the cell making sure the spindle 
components are ready for mitosis. M is where the nuclear 
division occurs, along with chromosome separation, and 
cytokinesis to bring about the creation of two daughter cells. 
 
3. Effects of hypothermic conditions on cell 
cycle progression and cytotoxicity  
 
For cells to proliferate they need both stimulation and 
progression factors [22] to enter the cycle. If one or more of 
these factors is thermally labile then non-optimal 
temperatures can create a different rate of loss, higher than 
that of the enzymatic production, causing different effects in 
the cell [23]. Cold treatment (cooling) is split into five 
categories; mild (35-33°C), moderate (31-29°C), low (24-
20°C), very low (20°C) and hypothermia (10-4°C) [24, 25]. 
In 1956, Cheveremont found that in primary embryo skeletal 
muscle cell cultures after 24h incubation at 16-20°C, the 
number of cells undergoing mitosis dropped to zero. 
However, after 3h of warming at physiological temperature 
(37°C) cells were dividing 2-3 times faster than the non-
cooled cells were [26]. The explanation provided for this was 
that the cells continue to progress through the cell cycle until 
they arrest at late G2. As might be expected, all phases of the 
cell cycle of mammalian cells are inhibited at temperatures 
lower than 10˚C (severe hypothermia) [27]. Culturing CHO 
(Chinese Hamster Ovary) cells at 30-35°C have been shown 
to demonstrate a reduction in the number of cells in G1 or S 
phases, whilst maintaining higher cell viability [4]. In 
addition, after reducing the temperature of cultured cells to 
16-20°C, rewarming has been found to increase the rate of 
cell division by 2-3 fold compared to non-cooled controls 
[27].  
 
Moreover, previous studies with mouse leukemic and HeLa 
cells showed prolongation of cell cycle at 25°C-33°C and a 
temporal dilation of the G1 and S phase. HeLa cells were 
cultured at different temperatures and this was shown to 
modify all phases of the cell cycle, whilst M phase was more 
sensitive than G1, S, G2 phases were to temperature [28]. 
Furthermore, Al Tameemi et al., 2014 showed that cooling 
during drug exposure may decelerate growth rates and thus 
protect cells from chemotherapy-induced toxicity [29]. There 
is some evidence that culturing cells at a reduced temperature 
can protect from cytotoxic agents modulating (preventing) 
the effects of chemotherapy drugs on the cell cycle [30]. 
 
As a result of difference stressors, such as oxidative stress, 
osmotic, and heat stress, gene expressions are changes, and 
the function of a gene product can be changed as well. For 
the rat model showing lethal hemorrhagic, there was clear 
evidence of hypothermia, which would u-regulate gene 
expressions in pro-survival pathways, with a down-regulation 
seen in metabolic pathways [31]. 
 
Normal human fibroblasts which has developed in cell 
culture displayed mild hypothermia (28°C) being the cause 
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for greater p53 levels and p21 activation. These cells go 
through a reversible G1/S cell cycle arrest, while cell cycle 
arrest through p21 is seen to have a protective effect on cells 
stemming from apoptosis brought on by cytotoxic agents [32, 
33] 
 
In addition, p53 has underlined the value of mediating this 
arrest, wild or defective p53 mouse embryo fibroblasts went 
through hypothermia. On the other hand, cells with wild-type 
p53 went through a cell cycle arrest , with the exception of 
defective p53, which denotes that p53 is important when it 
comes to mediation [33]. Due to the fact that numerous 
tumours include p53 mutants, hypothermia is considered to 
raise the selective toxicity of chemotherapeutic agents for 
tumour cells [32, 33], and mild hypothermia (or cooling) is 
employed widely, in order to mitigate hair loss through 
chemotherapy  [29, 34]. 
 
Several studies have confirmed that this condition delays cell 
growth, decreases hair matrix keratinocyte growth rate and 
shows a delay in the progression of the cell cycle, while 
maintaining high cell viability. Moreover, cooling induces a 
decrease in the rates of nutrient consumption and toxic 
metabolite production, as well as a decrease in protease 
activity and the production of reactive oxygen species [35].  
 
4. Cooling research aims 
 
Most chemotherapeutic agents trigger apoptosis in dividing 
cells [36]. Because of the rapid division rate of hair matrix 
keratinocytes, the hair follicle (HF) represents a target for 
many chemotherapeutic agents [37]. 
 
Chemotherapy-induced alopecia (CIA) is considered to be 
the most traumatic side effect of cancer treatment, and stress 
caused by this can have a negative impact on the overall 
outcomes [38, 39]. Cancer patients going through 
chemotherapy may lose their hair all over their bodies, but it 
is the most traumatic for patients to lose the hair on their 
heads. Scalp HFs are more affected by chemotherapy drugs 
than other terminal HFs, for example those of the eyebrows, 
eyelashes, beard, auxiliary and pubic hairs that are variably 
affected [37]. HFs across various regions of the body has 
variable durations of anagen. For example, scalp HFs stay in 
the anagen stage for 2-6 years and ultimately produce long 
hairs, whereas actively growing eyebrow follicles remain in 
the anagen stage for between 2-3 months. In the HFs of eye 
lashes, this stage lasts between 30 and 45 days, producing 
short hairs [40, 41]. Furthermore, in terms of eyelash HFs, 
only around 40% of the upper lashes and 15% of the lower 
lashes are in the anagen phase at any point, whereas for scalp 
hair, 80-85% are undergoing the anagen phase [40]. Eyebrow 
and eyelash HFs maintain the slowest hair growth rate for 
any area of the body. Due to the greater mitotic activity, 
anagen follicles have the greatest vulnerability to toxicity. 
Therefore, regions with the greatest proportion of anagen 
follicles, for example the scalp, are traumatised more 
severely by noxious events compared with regions 
comprising a lower proportion of anagen follicles, for 
example the eyelashes [42, 43]. 
The only effective treatment for CIA currently available is 
scalp cooling [44]. The scalp cooling involves Refrigeration 
unit-fitted machines, designed to circulate liquid refrigerant 
through a cooling cap during chemotherapy treatments [45]. 
It has been hypothesised that scalp cooling works by a 
combination of vasoconstriction, a reduction in the metabolic 
rate and/or reduced drug uptake by cells in the hair bulb [46]. 
 
5. Conclusion 
 
It is widely thought that understanding the processes behind 
the control of cell cycle progression as a result of drug 
treatment at physiological temperature and cooling is crucial 
to comprehending the pathways in charge of the benefits 
cooling offers against drug toxicity, and specifically in the 
matter of protection. It can be seen that there are not many 
research study papers in existence, which look into the 
reaction seen for a number of temperatures, which can assist 
in optimising cooling and investigating a number of different 
temperatures to achieve this. The end goal would be to 
protect against cell damage brought on through 
chemotherapy via the initiation of a reversible cell cycle 
arrest. Overall, cooling is seen to be able to achieve short 
term reversible cell cycle arrest in cell culture, which puts 
forward the idea cooling has the potential to allow for 
selective toxicity of chemotherapeutic agents for cells to be 
reached optimally. Even though there is available clinical 
evidence on the matter, the processes behind the way cooling 
acts as a protection are not comprehended to a satisfactory 
degree, particularly when it comes to looking into the 
positive effect of cooling and direct protection from CIA. It 
is suggested that the cytoprotective impact of cooling when 
dealing with toxicity brought on by chemotherapy is because 
of its capacity to lower cell proliferation rates. 
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